Introduction
The neural cell adhesion molecule (N-CAM or CD56) is known to be initially expressed in three different embryonic germ layers. 1 In the adult, although predominantly found in cells of neural origin, N-CAM can be detected in a wide variety of cell types. In haematopoetic cells, N-CAM has only been observed on a subset of human blood lymphocytes which are involved in non-MHC (major histocompatibility complex) restricted cytotoxicity. 2 A striking difference between normal plasma cells and their malignant counterparts in multiple myeloma (MM), is the upregulation of the neural cell adhesion molecule on the myeloma cells. [3] [4] [5] The expression of N-CAM on MM cells represents, however, not a unique phenomenon in neoplasms; its expression is also shown in tumours of neural and muscle origin, as well as in melanomas, small cell lung cancer, Ewing's sarcoma and Wilms' tumour. 6, 7 CD56 expression has also been reported in haematological malignancies such as acute leukaemia, chronic myeloid leukaemia and lymphoma etc. [8] [9] [10] [11] [12] [13] [14] N-CAM mediates adhesive interactions between cells in a homo-as well as in a heterophilic way. 15, 16 Although N-CAM is encoded by a single gene, located on chromosome 11 at band q23-24, several different structural variants of the protein can be generated by mechanisms of alternative splicing, 17 and by the insertion of small exons. 18 The different N-CAM variants show structural similarities, mainly in their extracellular domain, but differ in the way they are anchored in the membrane. Of the three major variants, the 180 and the 140 kDa Correspondence: C De Greef; Fax: 32 2 477 67 27 Received 28 March 1997; accepted 1 October 1997 isoforms are associated with the membrane via a transmembrane domain, while the 120 kDa variant uses a glycosyl phos-phatidyl inositol anchor.
Recently, the human N-CAM promoter region was cloned and characterized. No TATA or CCAAT elements could be found in the DNA spanning the 5′ end of the N-CAM gene. Its location in a GC-rich domain makes the N-CAM promoter comparable to promoters of the so-called 'housekeeping genes'. 19 At present, several studies focus on the differential expression of N-CAM during development, trying to determine the control mechanisms that regulate the subsequent changing features of the protein as well as its changing pattern of expression and function. Also in MM, the expression of N-CAM is shown to be variable. More than 80% of newly diagnosed MM patients have CD56-positive myeloma cells. During the refractory or extramedullary phase CD56 expression is decreased. 20 Based on the observation that CD56 is involved in the cellular contact between the osteoblasts and the myeloma cells, a role for N-CAM in the pathophysiology of myeloma and in the dissemination of the tumour cells, after loss of the molecule, has been suggested. 21 In previous studies we showed that the N-CAM isoform expressed on the myeloma cells corresponds to the 140 kDa variant, 4 which is anchored via a transmembrane domain in the membrane.
In this study, we examined N-CAM expression at the molecular level in a panel of MM cell lines. Via Northern blot analysis, N-CAM-specific transcripts were found to be restricted, with one exception, to the N-CAM-positive cell lines. No differences in the genomic organization of the N-CAM gene in N-CAM-positive and N-CAM-negative MM cell lines were detected. In order to check whether the N-CAM gene expression in MM is regulated at the transcriptional level, transfection experiments of N-CAM promoter constructs in N-CAM-negative cells were performed.
Materials and methods

Cell lines
The origin and main features of the MM cell lines used have been described. Fravel, 22 Karpas 707, 23 Fractionation of LB84-1 in an N-CAM-positive and an N-CAM-negative cell population
The LB84-1 MM cell line, which is partially N-CAM positive (±20%), was fractionated in an N-CAM-positive and an N-CAM-negative subpopulation, using magnetic beads. Cells were incubated with anti-CD56 antibodies (Leu19; Becton Dickinson, Erembodegem, Belgium), at a concentration of 10 g/20 × 10 6 cells/ml and at 4°C for 30 min. After two washes with RPMI with 5% alpha supplemented (Hyclone; Greiner, Wemmel, Belgium), cells were mixed with goat antimouse-IgG-coated magnetic beads (Dynal, Medichim, Heppignies, Belgium) at a ratio of 1 cell per 10 beads. After rotating this mixture for 1 h at 4°C, the N-CAM-positive cells were separated from the negative ones using a flat samarium cobalt magnet.
The N-CAM-negative fraction was tested for contaminating N-CAM-positive cells using the immunogold silver staining method. 36 Southern blot analyses DNA extraction and gel electrophoresis were performed as described. 37 In the first analysis, 20 g of DNA from the panel of MM lines and from KG1a was digested with HindIII. In the second analysis, 20 g of DNA, extracted from the LB84-1 subfractions and from KG1a, were digested with HindIII or EcoRI or BamHI. The DNA was then transferred by capillary blotting to HybondN + (Amersham, Brussels, Belgium) in 20 × SSC and fixed to the membrane by alkaline treatment. Hybridizations with the N-CAM-specific cDNA probe were performed overnight in 50% formamide/2 × SSC (0.3 M NaCl, 0.03 M sodium citrate)/5 × Denhardt's solution (1 × Denhardt's = 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% BSA)/0.1% SDS/100 g/ml salmon sperm DNA at 42°C. Post-hybridization washes were done in 0.1 × SSC/0.1% SDS at 65°C.
The N-CAM-specific cDNA (kindly provided by Dr Barton, University of Cambridge, UK) was purified from the vector and radio-labelled by random primed DNA elongation. 38 Northern blot analyses mRNA from 5 × 10 7 cells was extracted with Pharmacia's Quick mRNA Purification Kit (Pharmacia, Roosendaal, The Netherlands). Gel electrophoresis of 5 g of mRNA was performed through gels containing formaldehyde. 37 The transfer of the RNA to nylon membranes (Gene Screen; Dupont, Brussels, Belgium or Fluka; Sigma, Bornem, Belgium) was performed as described above. Pre-and hybridization conditions were as described for the Southern blot analyses. Posthybridization washes were done in 0.2 × SSC/0.1% SDS at 65°C. The N-CAM-specific cDNA probe was used as well as the glyceraldehyde 3 phosphate dehydrogenase (GAPDH) probe 39 as a control for the quality and quantity of the RNA.
PCR analyses
An N-CAM-specific fragment of 337 bp was amplified using a synthetic 23-mer (5′CCCGAATTCATCCTTGTTCAAGC-3′) and a 25-mer (5′TCGGGATCCGGACTGGCTGCGTCTT-3′).
Starting from 200 ng of mRNA or 2 g of total RNA, first strand cDNA was synthesized using the Superscript Preamplification System (Life Technologies, Merelbeke, Belgium). This cDNA was used in a 50-fold dilution in a PCR reaction containing 2 mM MgCl 2 , 0.2 mM dNTP and 0.2 M primers with Taq polymerase (Life Technologies). Forty PCR cycles were applied as follows: 30 s at 94°C, 30 s at 55°C and 30 s at 72°C. A control PCR without template was included. In order to detect amplification products more sensitively, the PCR products were analysed on an 1.5% agarose/TBE gel and transferred to a nylon membrane (Fluka). Hybridization conditions were as described above or without formamide at 65°C.
Transfections
A chimaeric gene construct, kindly provided by Dr Barton, in which the N-CAM promoter precedes a chloramphenicol acetyl transferase (CAT) reporter gene, 19 was used to measure the N-CAM promoter activity in an N-CAM-negative cell line (L363). As a positive control, a constitutively CAT-expressing plasmid pcDNA/CAT, containing the CAT gene under the control of the CMV promoter was used (Invitrogen, Leek, The Netherlands). As a negative control pcDNA3, lacking the CAT gene, was used. All plasmids express the Neo gene.
After culturing, 10 7 cells were harvested, resuspended in 0.8 ml of RPMI medium containing 10% FCS and transferred into a plastic electroporation cuvet. Thirty micrograms of plasmid were added to the cell line suspension and left at room temperature for 1 min. Electroporation was carried out at 300 V and 2100 F, and at 300 V and 2250 F, using the Easyject electroporation unit (Eurogentec, Seraing, Belgium). After pulsing, the cells were transferred into flasks, containing 10 ml of RPMI/10%FCS. After 72 h, the cells were harvested and resuspended in 10 ml RPMI/10% FCS containing 2.5 mg/ml G418 (Geneticin; GIBCO BRL, Merelbeke, Belgium) in order to select cells for neo gene expression.
Chloramphenicol acetyl transferase (CAT) assays
CAT was quantitatively measured making use of Boehringer's CAT ELISA (Boehringer Mannheim, Brussels, Belgium). The cell extracts were prepared according to the manufacturer's instructions, and the protein concentration was determined using the Bradford technique. 40 
Results
Detection of the N-CAM gene in N-CAM-positive and N-CAM-negative cell lines Table 1 Table 1 Characteristics of chromosome 11 in myeloma cell lines probe showed the differences in the amount of mRNA present. This clearly confirms that the absence of N-CAM transcripts is not due to a lesser amount of RNA applied. In order to enhance the sensitivity level of detection and to exclude the possibility that degradation of the large RNA results in the reduction of the N-CAM transcripts in the N-CAM-negative cell lines, a PCR was performed using N-CAM-specific primers. Except for the EJM cell line, these PCR analyses only showed reproducible amplification products in the N-CAMpositive cell lines (Figure 3) . In order to exclude false negativity in the samples derived from N-CAM-negative cells, N-CAM-specific PCR was performed in the presence of the actin primers ( Figure 4 ). Next to a strong actin PCR product, present in all the samples tested, staining with ethidium bromide only revealed the smaller N-CAM amplification product in the strongest N-CAM-expressing cells (KG1a and OPM-1). Using the N-CAM-specific probe weaker signals could also be detected. This analysis again confirmed, with the exception of EJM, the correlation between the presence of N-CAM transcripts and the expression of the protein. Occasionally, a weak N-CAM amplification product was obtained in N-CAMnegative cells (other than EJM) after 40 PCR cycles. These signals were, however, not reproducible in all the PCRs performed nor in all the cDNA preparations tested.
After sorting the LB84-1 cell line in its N-CAM-positive and N-CAM-negative fraction, the N-CAM-negative fraction was also tested in a Northern blot analysis with the N-CAMspecific probe. This clearly reveals the presence of the N-CAM transcripts in the cell fraction depleted of N-CAM-positive cells ( Figure 5 ). The intensities of the N-CAM-specific signals before and after removal of the N-CAM-positive cells show comparable amounts of N-CAM mRNA. The quantity of mRNA applied was verified in a control hybridization with GAPDH. The purity of the N-CAM negative cell fraction was tested using immunogold silver staining. This showed the presence of a minority (±1%) of remaining N-CAM-positive cells in the N-CAM-negative cell fraction.
N-CAM promoter activity in an N-CAM-negative cell line
In order to check whether N-CAM-negative MM cell lines transcriptionally regulate the N-CAM gene, we transfected the L363 line with a plasmid containing the CAT gene under the control of the N-CAM promoter. To measure the promoter strength, CAT amounts were measured in transfected L363 extracts. An enzyme immunoassay was used for the quantitative determination of CAT. Figure 6 shows the results of this In this study, we examined the molecular mechanisms leading to this differential N-CAM expression in MM. We focused on a panel of MM cell lines characterized by a varying expression of N-CAM. In order to check whether lack of N-CAM expression is caused by changes in the genomic organization of the coding gene, we performed Southern blot analyses with an N-CAM-specific cDNA probe. No differences in hybridization pattern could be found between the different cell lines. The differences in intensity of the signals reflect the differences in amount applied. However, since this technique focuses on relatively small differences in the sequence of the studied fragments, more drastic genomic abnormalities like translocations further up-or downstream could not be excluded. Since is was shown in a particular case of Ewing's sarcoma that N-CAM expression might be associated with chromosomal abnormalities, 41 and since in MM chromosomal changes often take place during disease progress, karyotype analysis was performed on the MM cell lines studied. However, no abnormalities were found in the chromosomal organization of the N-CAM gene, indicating that N-CAM expression depends rather on transcriptional regulation.
Northern blot analyses with the N-CAM cDNA probe revealed that, with one exception, N-CAM transcripts could exclusively be found in the N-CAM expressing lines. In order to exclude sensitivity problems to detect the transcripts, PCR analyses were performed using N-CAM-specific primers.
These analyses confirmed the presence of N-CAM transcripts in the N-CAM expressing cells. In a few cases, weak N-CAMspecific amplification products were observed in N-CAMnegative samples. After testing several batches of RNA and after repeating the PCR, these signals, however, could not be consistently obtained. Whether the reproducible presence of N-CAM transcripts found in the CD56-negative EJM cell line reflects the peculiar organization of the N-CAM-bearing chromosome (+11p, +11p) in this cell line, remains unsolved. It cannot be excluded that this MM cell line produces the N-CAM soluble form and therefore was found to be negative for CD56 at the surface of the cells in gold silver staining.
For the LB84-1 cell line, after isolating the N-CAM-negative cells, Northern blot analysis did not reveal a different RNA pattern that could explain the lack of detectable surface N-CAM expression.
To check whether differences in transcriptional activity between N-CAM-positive and -negative cell lines are due to structural differences in the promoter region, sequence analysis of this region was performed (data not shown). As the promoter activity of N-CAM was measured with deletion constructs, we focused on that part of the promoter showing the highest activity. We could, however, not find major differences in this region between N-CAM-negative and N-CAM-positive MM cells, especially not in the sequences that harbour transcription factor binding sites. 19 Since these results indicate a transcriptional control of the N-CAM gene in MM by a not yet identified factor, we decided to check whether this expression could be explained by the existence of regulatory elements present in the N-CAMpositive MM cell lines but absent in the N-CAM-negative ones. Based on the observation that N-CAM expression on myeloma cells correlates with medullary localization, it has been postulated that the dissemination of the myeloma cells involves down-regulation of the molecule. 20 This might indicate the existence of a complex network, in which a cis-acting gene activating element plays a key role.
Therefore, we examined the N-CAM promoter activity in N-CAM-negative cells. Making use of a CAT assay, in which the amount of CAT, produced under the control of the N-CAM CAT amounts were measured in L363 cells transfected with the following constructs: −CAT the negative control construct lacking the CAT gene; +CAT (CMV), the positive control construct, constitutively expressing CAT; +CAT (N-CAM), the N-CAM promoter construct in which the N-CAM promoter region precedes the CAT reporter gene. The CAT ELISA is based on the sandwich-enzyme-immunoassay principle, using anti-CAT antibodies prebound on the surface of the microtitre plate modules to which the cell extracts are added. CAT, if present in the cell extracts, binds to these antibodies and subsequently binds a digoxigenin-labelled antibody to CAT. Following this, an antibody to digoxigenin conjugated to peroxidase is added and finally the peroxidase substrate (ABTS) is added. The absorbance of the samples is determined using an ELISA reader and represents the CAT level in the extracts tested.
promoter, was measured, we showed that N-CAM promoter activity in N-CAM-negative cells is comparable to the activity of a constitutively activated promoter. Based on this observation it can be assumed that in some of the N-CAM-negative cell lines a basal transcription level of the N-CAM gene is sustained. Therefore, the weak N-CAM amplification products occasionally obtained in the non-expressing cells might reflect such a low expression without the detectable production of the N-CAM protein.
This study shows that in MM, CD56 expression does not seem to depend on a simple mechanism of activation, but more likely results from the interplay of several factors, of which key elements like cytokines and transcription factors still have to be determined.
Since the discovery of Kaposi's sarcoma-associated herpesvirus (KSHV) in BM dendritic cells of MM patients, 42 new interest has been taken in the function of N-CAM expression in myeloma tumorigenesis. Close interactions take place between the myeloma cells and other cells present in the BM compartment via a variety of adhesion molecules. Expression of N-CAM in the BM myeloma cells has already been suggested to allow local accumulation of the tumour cells as well as interaction with stromal cells and osteoblasts. 43 Since KSHV seems to harbour an N-CAM homolog in its genome, expression of this viral protein in the dendritic cells might allow homophilic interactions between the N-CAM-positive myeloma cells and the KSHV-positive dendritic cells.
Performing a PCR amplification with viral specific primers, 44 we found no detectable levels of KSHV DNA in the MM cell line panel used in this study (unpublished results) . This observation corresponds with the fact that the virus does not infect the myeloma cells and shows that N-CAM expression in the tumour cells is not due to viral sequences encoding an N-CAM homolog.
Whether N-CAM mediates adhesion between KSHVinfected dendritic cells and N-CAM-positive MM cells remains to be elucidated and might help to unravel the role of KSHV in the pathogenesis of MM.
